Comparison of Optimised MDI versus Pumps with or without Sensors in Severe Hypoglycaemia (the Hypo COMPaSS trial)
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Background: Severe hypoglycaemia (SH) is one of the most feared complications of type 1 diabetes (T1DM) with a reported prevalence of nearly 40%. In randomized trials of Multiple Daily Injections (MDI) and Continuous Subcutaneous Insulin Infusion (CSII) therapy there is a possible benefit of CSII in reducing SH. However few trials have used basal insulin analogues as the basal insulin in the MDI group and individuals with established SH have often been excluded from prospective studies. In published studies investigating the effect of Real Time Continuous Glucose Monitoring (RT-CGM) benefit in terms of reduced SH has not yet been demonstrated. The primary objective of this study is to elucidate whether in people with T1DM complicated by impaired awareness of hypoglycaemia (IAH), rigorous prevention of biochemical hypoglycaemia using optimized existing self-management technology and educational support will restore awareness and reduce risk of recurrent SH. Methods/design: This is a multicentre prospective RCT comparing hypoglycaemia avoidance with optimized MDI and CSII with or without RT-CGM in a 2×2 factorial design in people with type 1 diabetes who have IAH. The primary outcome measure for this study is the difference in IAH (Gold score) at 24 weeks. Secondary outcomes include biomedical measures such as HbA1c, SH incidence, blinded CGM analysis, self monitored blood glucose (SMBG) and response to hypoglycaemia in gold standard clamp studies. Psychosocial measures including well-being and quality of life will also be assessed using several validated and novel measures. Analysis will be on an intention-to-treat basis. Discussion: Most existing RCTs using this study’s interventions have been powered for change in HbA1c rather than IAH or SH. This trial will demonstrate whether IAH can be reversed and SH prevented in people with T1DM in even those at highest risk by using optimized conventional management and existing technology. Trial Registration: ISRCTN52164803 Eudract No: 2009-015396-27
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tesfaye, S., Boulton, A. J. M., Dyck, P. J., Freeman, R., Horowitz, M., Kempler, P., Lauria, G., Malik, R. A., Spallone, V., Vinik, A., et al. (2010) · Diabetes Care · doi:10.2337/dc10-1303 · Cited by 2,690
Continuous glucose monitoring and intensive treatment of type 1 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805017 · Cited by 1,559
Cryer, P. E., Davis, S. N., & Shamoon, H. (2003) · Diabetes Care · doi:10.2337/diacare.26.6.1902 · Cited by 1,160 · cited 2×
“Moreover, success has previously been confined to those with relatively short duration of diabetes [7] or transiently following a brief period of absolute hypoglycaemia avoidance in those with longer duration diabetes [8].”
BackgroundEffectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes
Bergenstal, R. M., Tamborlane, W. V., Ahmann, A., Buse, J. B., Dailey, G., Davis, S. N., Joyce, C., Peoples, T., Perkins, B. A., Welsh, J. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002853 · Cited by 894 · cited 1×
“Studies that have compared RT-CGM integrated with CSII with analogue regimens have also failed to demonstrate a difference in rates of SH although they have suggested reduced HbA1c with the technology [37,38].”
BackgroundEpidemiology of severe hypoglycemia in the diabetes control and complications trial
(1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)80085-z · Cited by 807
Epidemiology of severe hypoglycemia in the Diabetes Control and Complications Trial
(1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)90605-w · Cited by 807
Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes.
Cryer, P. (2002) · Diabetologia · doi:10.1007/s00125-002-0822-9 · Cited by 794 · cited 1×
“Despite 90 years’ clinical experience with insulin replacement therapy, however, severe hypoglycaemia (SH) remains the major factor limiting optimal glycaemic control [4].”
BackgroundClarke, W. L., Cox, D. J., Gonder-Frederick, L. A., Julian, D., Schlundt, D., & Polonsky, W. (1995) · Diabetes Care · doi:10.2337/diacare.18.4.517 · Cited by 651
Deiss, D., Bolinder, J., Riveline, J.-P., Battelino, T., Bosi, E., Tubiana-Rufi, N., Kerr, D., & Phillip, M. (2006) · Diabetes Care · doi:10.2337/dc06-1134 · Cited by 539
Self-citationMisso, M. L., Egberts, K. J., Page, M., O'Connor, D., & Shaw, J. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005103.pub2 · Cited by 406
Self-citation
Cited by
Little, S. A., Leelarathna, L., Walkinshaw, E., Tan, H. K., Chapple, O., Lubina-Solomon, A., Chadwick, T. J., Barendse, S., Stocken, D. D., Brennand, C., et al. (2014) · Diabetes Care · doi:10.2337/dc14-0030 · Cited by 237
Self-citationLittle, S. A., Speight, J., Leelarathna, L., Walkinshaw, E., Tan, H. K., Bowes, A., Lubina-Solomon, A., Chadwick, T. J., Stocken, D. D., Brennand, C., et al. (2018) · Diabetes Care · doi:10.2337/dc17-2682 · Cited by 86
Self-citationSpeight, J., Barendse, S. M., Singh, H., Little, S. A., Inkster, B., Frier, B. M., Heller, S. R., Rutter, M. K., & Shaw, J. A. M. (2016) · Diabetic Medicine · doi:10.1111/dme.12824 · Cited by 76
Self-citationRestoration of Self-Awareness of Hypoglycemia in Adults With Long-Standing Type 1 Diabetes
Leelarathna, L., Little, S. A., Walkinshaw, E., Tan, H. K., Lubina-Solomon, A., Kumareswaran, K., Lane, A. P., Chadwick, T., Marshall, S. M., Speight, J., et al. (2013) · Diabetes Care · doi:10.2337/dc13-1004 · Cited by 56
Self-citationClinical approaches to treat impaired awareness of hypoglycaemia
Farrell, C. M., & McCrimmon, R. J. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188211000248 · Cited by 31
Metadata
- Authors
- Little, S., Chadwick, T., Choudhary, P., Brennand, C., Stickland, J., Barendse, S., Olateju, T., Leelarathna, L., Walkinshaw, E., Tan, H. K., Marshall, S. M., Thomas, R. M., Heller, S., Evans, M., Kerr, D., Flanagan, D., Speight, J., & Shaw, J. A.
- Venue
- BMC Endocrine Disorders
- Published
- 2012-12
- Volume
- 12
- Issue
- 1
- Pages
- 33-33
- ISSN
- 1472-6823 (ISSN-L)
- OpenAlex
- W2076436913
- Cited by
- 27
- References
- 18
- FWCI
- 2.30
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparison of Optimised MDI versus Pumps with or without Sensors in Severe Hypoglycaemia (the Hypo COMPaSS trial). https://app.cochat.ai/papers/10.1186/1472-6823-12-33
- The paper
- Little, S., Chadwick, T., Choudhary, P., Brennand, C., Stickland, J., Barendse, S., Olateju, T., Leelarathna, L., Walkinshaw, E., Tan, H. K., Marshall, S. M., Thomas, R. M., Heller, S., Evans, M., Kerr, D., Flanagan, D., Speight, J., & Shaw, J. A. (2012). Comparison of Optimised MDI versus Pumps with or without Sensors in Severe Hypoglycaemia (the Hypo COMPaSS trial). BMC Endocrine Disorders. https://doi.org/10.1186/1472-6823-12-33
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.